Aerie Pharmaceuticals to Announce First Quarter 2017 Financial Results and Host Conference Call on Tuesday, May 2, 2017
April 25 2017 - 7:30AM
Business Wire
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), (the “Company”),
announced today that its first quarter 2017 financial results will
be released after the market closes on Tuesday, May 2, 2017.
Following the release, the Company will host a live conference call
and webcast at 5:00 p.m. Eastern Time to discuss the Company’s
financial results and provide a general business update.
The live webcast and a replay may be accessed by visiting the
Company's website at http://investors.aeriepharma.com. Please
connect to the Company's website at least 15 minutes prior to the
live webcast to ensure adequate time for any software download that
may be needed to access the webcast. Alternatively, please call
(888) 734-0328 (U.S.) or (678) 894-3054 (international) to listen
to the live conference call. The conference ID number for the live
call is 7178517. Please dial in approximately 10 minutes prior to
the call. Telephone replay will be available approximately two
hours after the call. To access the replay, please call (855)
859-2056 (U.S.) or (404) 537-3406 (international). The conference
ID number for the replay is 7178517. The telephone replay will be
available until May 9, 2017.
About Aerie Pharmaceuticals, Inc.
Aerie is a clinical-stage pharmaceutical company focused on the
discovery, development and commercialization of first-in-class
therapies for the treatment of patients with glaucoma and other
diseases of the eye. Aerie's two lead product candidates are
once-daily intraocular pressure-lowering therapies with novel
mechanisms of action to treat patients with glaucoma or ocular
hypertension. The NDA for RhopressaTM (netarsudil ophthalmic
solution) 0.02% was submitted to the FDA in February 2017. Aerie's
second product candidate, RoclatanTM (netarsudil/latanoprost
ophthalmic solution) 0.02%/0.005%, which is a fixed dose
combination of RhopressaTM and widely prescribed PGA latanoprost,
currently has two Phase 3 registration trials underway, named
Mercury 1 and Mercury 2. If these trials are successful, a
RoclatanTM NDA submission is expected to take place in late 2017 or
early 2018. Aerie is also focused on the development of additional
product candidates and technologies in ophthalmology.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170425005119/en/
Aerie PharmaceuticalsRichard Rubino,
908-947-3540rrubino@aeriepharma.comorBurns McClellan, Inc., on
behalf of Aerie PharmaceuticalsInvestorsAmi Bavishi,
212-213-0006abavishi@burnsmc.comorMediaJustin Jackson,
212-213-0006jjackson@burnsmc.com
Aerie Pharmaceuticals (NASDAQ:AERI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Aerie Pharmaceuticals (NASDAQ:AERI)
Historical Stock Chart
From Sep 2023 to Sep 2024